Rare complex mutational profile in an ALK inhibitor-resistant non-small cell lung cancer
EM Azzato, C Deshpande, V Aikawa… - Anticancer …, 2015 - ar.iiarjournals.org
Testing for somatic alterations, including anaplastic lymphoma receptor tyrosine kinase
gene (ALK) rearrangements and epidermal growth factor receptor gene (EGFR) mutations …
gene (ALK) rearrangements and epidermal growth factor receptor gene (EGFR) mutations …
[HTML][HTML] Complex genetic alterations contribute to rapid disease progression in an ALK rearrangement lung adenocarcinoma patient: a case report
X Long, H Wu, C Yang, F Li, M Zhang… - Translational Cancer …, 2021 - ncbi.nlm.nih.gov
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been found to
significantly improve the quality of life and survival in ALK-positive non-small cell lung …
significantly improve the quality of life and survival in ALK-positive non-small cell lung …
Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and …
P Ulivi, E Chiadini, C Dazzi, A Dubini, M Costantini… - Clinical lung cancer, 2016 - Elsevier
Background Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like …
oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like …
Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice
P Jamme, C Descarpentries, R Gervais, E Dansin… - Clinical Lung Cancer, 2019 - Elsevier
Background Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have
shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but …
shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but …
[PDF][PDF] Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma?
Genetic alterations in the anaplastic lymphoma kinase gene (ALK) that result in fusion
proteins are detected in approximately 1% to 2% of unselected non–small-cell lung cancer …
proteins are detected in approximately 1% to 2% of unselected non–small-cell lung cancer …
[HTML][HTML] Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
H Hu, H Dai, L Ding - Translational Cancer Research, 2022 - ncbi.nlm.nih.gov
Background Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver
promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK …
promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK …
Primary resistance to ALK inhibitor in ALK-positive non-small-cell lung cancer.
J Kang, H Chen, Q Zhou, HY Tu, XC Zhang, S Jian… - 2017 - ascopubs.org
9063 Background: Crizotinib is a standard of care in anaplastic lymphoma kinase (ALK)-
positive advanced non-small-cell lung cancers (NSCLC). Undoubtedly, the resistance to …
positive advanced non-small-cell lung cancers (NSCLC). Undoubtedly, the resistance to …
[HTML][HTML] An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer
Y Togashi, H Mizuuchi, Y Kobayashi, H Hayashi… - Annals of …, 2015 - Elsevier
The detection of ALK rearrangements is mainly performed using fluorescence in-situ
hybridization (FISH). However, such analyses can yield false-positive and false-negative …
hybridization (FISH). However, such analyses can yield false-positive and false-negative …
The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options–an overview
B Solomon, JC Soria - Annals of Oncology, 2016 - annalsofoncology.org
The identification of rearrangements in the anaplastic lymphoma kinase (ALK) gene in 3%-
7% of patients with non-smallcell lung cancer (NSCLC) and subsequent demonstration of …
7% of patients with non-smallcell lung cancer (NSCLC) and subsequent demonstration of …
[HTML][HTML] How I treat ALK-positive non-small cell lung cancer
Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell
lung cancer (NSCLC) and subsequent development of increasingly effective and central …
lung cancer (NSCLC) and subsequent development of increasingly effective and central …